All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

October 9th 2024

The FDA has granted orphan drug designation to namodenoson for the treatment of patients with pancreatic cancer.

LBL-024 Receives Breakthrough Therapy Designation in China for Extrapulmonary Neuroendocrine Carcinoma

October 9th 2024

LBL-024 received breakthrough therapy designation in China for pretreated advanced extrapulmonary neuroendocrine carcinoma.

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

October 9th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma

October 9th 2024

Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.

Apalutamide Demonstrates Real-World OS Benefit vs Enzalutamide in mCSPC

October 9th 2024

Apalutamide was associated with an improved 24-month overall survival rate vs enzalutamide in metastatic castration-sensitive prostate cancer.

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

October 8th 2024

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

October 8th 2024

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

October 8th 2024

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.

Fox Chase Cancer Center Welcomes Dr Alexander R. Vartanov

October 8th 2024

Fox Chase Cancer Center hired Alexander R. Vartanov, MD, as an assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.

Phase 3 Study of TAR-200/Cetrelimab Is Discontinued in MIBC

October 8th 2024

The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.

Perioperative Pembrolizumab Meets EFS End Point in Newly Diagnosed, Resected Stage III/IVA HNSCC

October 8th 2024

Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.

PARP1-Selective Inhibitors Generate Excitement in Solid Tumors

October 8th 2024

Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.

D-VRd Propels Toward SOC Status in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

October 8th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

October 8th 2024

Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC

October 7th 2024

Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

October 7th 2024

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Gotistobart Plus Pembrolizumab Shows Activity in Platinum-Resistant Ovarian Cancer

October 7th 2024

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

Cigall Kadoch, PhD, Wins Prestigious Blavatnik National Award

October 7th 2024

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Health Canada Expands Indication for Illuccix Diagnostic Kit for PSMA-Targeted Radioligand Therapy in mCRPC

October 7th 2024

Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML

October 7th 2024

ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.